116289-59-9Relevant articles and documents
HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6
-
Paragraph 00503-00504; 00548-00550, (2021/09/04)
The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.
Diarylether inhibitors of farnesyl-protein transferase
Dinsmore, Christopher J.,Williams, Theresa M.,Hamilton, Kelly,O'Neill, Timothy J.,Rands, Elaine,Koblan, Kenneth S.,Kohl, Nancy E.,Gibbs, Jackson B.,Graham, Samuel L.,Hartman, George D.,Oliff, Allen I.
, p. 1345 - 1348 (2007/10/03)
The design and synthesis of simple nonpeptide inhibitors of farnesyl-protein transferase (FTase) are described. Cysteine-derived diarylether frameworks are appropriate structural replacements for the C-terminal tetrapeptide portion of the Ras protein, and possess in vitro potency against FTase. Inhibitory activity is dependent on the ring-substitution pattern, and does not require the presence of a C-terminal carboxylate group.